J. Griggs, P. Mangu, and H. Anderson, Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.30, issue.13, pp.1553-1561, 2012.
DOI : 10.1200/JCO.2011.39.9436

A. Gutiérrez, L. Bento, and A. Bautista-gili, Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14, PLOS ONE, vol.21, issue.7, 2015.
DOI : 10.1371/journal.pone.0123978.t004

B. Coiffier, E. Lepage, and J. Briere, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-242, 2002.
DOI : 10.1056/NEJMoa011795

L. Gouill, S. Milpied, N. Lamy, and T. , First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.8003, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.8003

C. Récher, B. Coiffier, and C. Haioun, Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial, The Lancet, vol.378, issue.9806, pp.1858-1867, 2011.
DOI : 10.1016/S0140-6736(11)61040-4

R. Delarue, H. Tilly, and N. Mounier, Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.6, pp.525-533, 2013.
DOI : 10.1016/S1470-2045(13)70122-0

E. Kempf, P. Hirsch, and M. Labopin, Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia, Leukemia Research, vol.38, issue.12, pp.1425-1429, 2014.
DOI : 10.1016/j.leukres.2014.09.013

A. Sparreboom, A. Wolff, and R. Mathijssen, Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese, Journal of Clinical Oncology, vol.25, issue.30, pp.4707-4713, 2007.
DOI : 10.1200/JCO.2007.11.2938

M. Hoffmann, R. Bergner, M. Stützle, M. Uppenkamp, and R. Foerster, Pharmacokinetics of Doxorubicin In Normal Weight and Obese Lymphoma Patients, Blood, vol.116, issue.21, pp.4935-4935, 2010.

J. Jones, L. Fayad, L. Elting, and M. Rodriguez, Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma, Leukemia & Lymphoma, vol.14, issue.9, pp.1649-1657, 2010.
DOI : 10.1001/jama.295.7.826

L. Weiss, T. Melchardt, and S. Habringer, Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma, Annals of Oncology, vol.119, issue.14, pp.171-176, 2014.
DOI : 10.1182/blood-2011-09-380949

H. Chan, S. Jackson, and J. Mclay, Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients, Leukemia & Lymphoma, vol.33, issue.11, pp.1-9, 2016.
DOI : 10.1093/annonc/mdt481

M. Lotrionte, G. Biondi-zoccai, and A. Abbate, Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity, The American Journal of Cardiology, vol.112, issue.12, pp.1980-1984, 2013.
DOI : 10.1016/j.amjcard.2013.08.026

A. Ganti, W. Liu, and S. Luo, Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, British Journal of Haematology, vol.854, issue.5, pp.699-702, 2014.
DOI : 10.1007/s00280-010-1487-6